Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.

By Yizhou Jiang, D. Ma, Chen Suo, Jinxiu Shi, Meng-zhu Xue, Xin Hu, Yi Xiao, Keda Yu, Yi-rong liu, Ying Yu and 33 more. Cancer Cell, 2019

862 citations recorded by the source corpus.

We comprehensively analyzed clinical, genomic, and transcriptomic data of a cohort of 465 primary triple-negative breast cancer (TNBC). PIK3CA mutations and copy-number gains of chromosome 22q11 were more frequent in our Chinese cohort than in The Cancer Genome Atlas. We classified TNBCs into four transcriptome-based subtypes: (1) luminal androgen receptor (LAR), (2) immunomodulatory, (3) basal-like immune-suppressed, and (4) mesenchymal-like. Putative therapeutic targets or biomarkers were identified among each subtype. Importantly, the LAR subtype showed more ERBB2 somatic mutations, infrequent mutational signature 3 and frequent CDKN2A loss. The comprehensive profile of TNBCs provided here will serve as a reference to further advance the understanding and precision treatment of TNBC.

Subfields: Cancer Research, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5aea98e51dfaa2800d8f5bfd74d4c2c4892737c8

Citations in the corpus

• Recent advances in therapeutic strategies for triple-negative breast cancer (2022, neutral): “classified TNBCs into 4 subtypes, including LAR, immunomodulatory, basal-like immune-suppressed, and mesenchymal-like, based on RNA sequencing, exome sequencing, and copy number array analyses of TNBC cases in China in 2019 [9].”